Compare Ascendis Pharma A/S (ASND) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Coursera Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Coursera Inc trades at $5.71 (market cap $1.64B). The key difference: Ascendis Pharma A/S is far larger — about 10.8× Coursera Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ASND | COUR | |
|---|---|---|
Market Cap | $17.74B | $1.64B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $12.70 |
52-Week Low | $163.32 | $5.09 |
Enterprise Value | $18.11B | $890.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Coursera (COUR) trades at $5.71, up 0.71% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $757.5M in 2025, though net losses persist at -$51M. The Udemy merger and a $500M share repurchase program are key developments. Cash flow from operations remains positive at $108.7M, supporting ongoing investments.
Wall Street analysts are generally optimistic with a $8.00 consensus price target, implying 40% upside. Risks include sustained profitability challenges and integration execution post-merger. The stock presents a growth opportunity if operational synergies materialize, but investors should weigh the high volatility and competitive pressures in edtech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
